

1 **Integrative transcriptomics analysis for uterine leiomyosarcoma identifies aberrant activation of cell**
2 **cycle-dependent kinases and their potential therapeutic significance.**

3

4 Kosuke Yoshida^{1,2,3}, Akira Yokoi^{1,2}, Tomofumi Yamamoto³, Yusuke Hayashi³, Jun Nakayama³, Tsuyoshi Yokoi⁴, Hiroshi
5 Yoshida⁵, Tomoyasu Kato⁶, Hiroaki Kajiyama¹, Yusuke Yamamoto³

6

7 ¹ Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya, Japan

8 ² Institute for Advanced Research, Nagoya University, Nagoya, Japan

9 ³ Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo, Japan

10 ⁴ Department of Drug Safety Sciences, Division of Clinical Pharmacology, Nagoya University Graduate School of
11 Medicine, Nagoya, Japan

12 ⁵ Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, Japan

13 ⁶ Department of Gynecology, National Cancer Center Hospital, Tokyo, Japan

14

15 **Running title: Integrative transcriptomics analysis for uterine leiomyosarcoma**

16

17 **Keywords:** uterine leiomyosarcoma, RNA-seq, cell cycle, PLK1, CHEK1,

18

19 **Additional information**

20 Financial support: This study was supported by JSPS KAKENHI Grant Numbers 21H02721, 21H03075, and
21 21K16789. Moreover, YOKOYAMA Foundation for Clinical Pharmacology (YRY-2115), Japan Research Foundation
22 for Clinical Pharmacology (2021A18), and Foundation for Promotion of Cancer Research in Japan supported as well.

23

24 Corresponding authors:

25 Akira Yokoi, M. D., Ph. D.

26 Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine

27 Tsuruma-cho 65, Showa-ku, Nagoya 466-8550, Japan

28 TEL: +81-52-744-2261

29 FAX: +81-52-744-2268

30 E-mail: ayokoi@med.nagoya-u.ac.jp

31

32 Yusuke Yamamoto, Ph.D.

33 Laboratory of Integrative Oncology, National Cancer Center Research Institute, Tokyo

34 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan

35 TEL: +81- 3-3452-2511, ext. 3664

36 FAX:+81-3-3543-9305

37 E-mail: yuyamamo@ncc.go.jp

38

39 A conflict of interest disclosure statement: The authors declare no potential conflicts of interest.

40

41 The word count: 4,314 words

42 The total number of figures and tables: five figures and one table

43

44 **Translational relevance**

45 The development of next-generation sequencing has had an immense impact on cancer research. However, the
46 biological features of uterine leiomyosarcoma are not fully understood. Hence, no effective treatment strategies have
47 been established based on its molecular background. In this research, we were able to assess the transcriptional
48 profiles of 46 patients with uterine leiomyosarcoma using three independent datasets and through the assistance of our
49 cohort. The integrative transcriptional analysis showed that the upregulation and activation of cell cycle-related genes
50 were the dominant features of uterine leiomyosarcoma. Afterward, we demonstrated that PLK1 or CHEK1 inhibition
51 induced cell cycle arrest and caused DNA damage, which resulted in cell death in leiomyosarcoma-derived cell lines.
52 Moreover, these drugs had a more significant anti-cancer effect in the mice model. These data suggest that
53 cell-cycle-dependent kinases represent novel therapeutic targets and could potentially improve the outcome for
54 patients with uterine leiomyosarcoma.

55

56 **Abstract**

57 **Purpose:** Uterine leiomyosarcoma is among the most aggressive gynecological malignancies. No effective treatment
58 strategies have been established. This study aimed to identify novel therapeutic targets for uterine leiomyosarcoma
59 based on transcriptome analysis and assess the preclinical efficacy of novel drug candidates.

30 **Experimental Design:** Transcriptome analysis was carried out using fresh-frozen samples of six uterine
31 leiomyosarcomas and three myomas. The Ingenuity Pathway Analysis was then used to identify potential therapeutic
32 target genes for uterine leiomyosarcoma. Moreover, our results were validated using three independent datasets,
33 including 40 uterine leiomyosarcomas. Then, the inhibitory effects of several selective inhibitors for the candidate
34 genes were examined using the SK-UT-1, SK-LMS-1, and SKN cell lines.

35 **Results:** We identified 512 considerably dysregulated genes in uterine leiomyosarcoma compared with myoma. The
36 Ingenuity Pathway Analysis showed that the function of several genes, including CHEK1 and PLK1, were predicted to
37 be activated in uterine leiomyosarcoma. Through an *in vitro* drug screening, PLK1 or CHEK1 inhibitors (BI 2536 or
38 prexasertib) were found to exert a superior anti-cancer effect against cell lines at low nanomolar concentrations and
39 induced cell cycle arrest. In SK-UT-1 tumor-bearing mice, BI 2536 monotherapy demonstrated a marked tumor
40 regression. Moreover, the prexasertib and cisplatin combination therapy also reduced tumorigenicity and prolonged
41 survival.

72 **Conclusion:** We identified the upregulated expression of *PLK1* and *CHEK1*; their kinase activity was considered to be
73 activated in uterine leiomyosarcoma. BI 2536 and prexasertib demonstrate a significant anti-cancer effect; thus, cell
74 cycle-related kinases may represent a promising therapeutic strategy for treating uterine leiomyosarcoma.

75

76

77 Introduction

78 Uterine sarcomas are a rare subset of gynecologic malignancies with an extremely aggressive behavior. Uterine
79 sarcomas are further classified into one of three groups: leiomyosarcoma (LMS), endometrial stromal sarcoma, and
80 adenosarcoma, of which LMS is the most common subtype (1,2). The annual incidence of uterine LMS (ULMS) is
81 approximately 0.86 per 100,000 women, and the majority of the patients are postmenopausal (3,4). Complete surgical
82 resection followed by adjuvant chemotherapy or radiation would be one of the reasonable management strategies for
83 patients with early-stage disease, although most patients eventually experience a recurrence (1,2). The combination of
84 docetaxel and gemcitabine has been widely used for patients with metastasis and seems to be partially effective (2).
85 However, over the last few decades, the median overall survival (OS) of patients with metastatic ULMS has only been
86 one or two years (4,5). Recently, novel agents, such as trabectedin, pazopanib, and eribulin, have been approved for
87 soft-tissue sarcomas. Despite high expectations for these agents, the prognosis of patients with ULMS has not
88 considerably improved (6-8). For example, a subgroup analysis showed that the median progression-free survival
89 (PFS) and OS for ULMS patients treated with trabectedin were 4.0 and 13.4 months, respectively (6). Similarly, other
90 clinical trials that evaluated pazopanib and eribulin for the treatment of ULMS showed a median OS of 17.5 and 12.7
91 months, respectively (7,8). Therefore, the clinical outcome of ULMS remains unsatisfactory, and new therapeutic
92 agents are urgently needed.

93 Recently, the development of next-generation sequencing has enabled the genomic landscape to shed light on a
94 variety of cancers. Several reports have revealed that alterations affecting *TP53*, *RBI*, *ATRX*, and *PTEN* frequently
95 occur in ULMS (9-12). Moreover, in some cases, fusion genes, such as *TNS1-ALK*, *ACTG2-ALK*, and
96 *KAT6B-KANSL1*, have been identified (12,13). Therefore, the genomic features of ULMS may be responsible for its
97 aggressiveness. Additionally, gene expression profiles provide important information for comprehending cancer
98 biology. However, only a few small-scale studies have been carried out at the RNA level in ULMS because RNA is
99 less stable than DNA, and samples are rare (12,14). In one study, Aurora A and B kinases were identified as potential
100 therapeutic targets in ULMS; however, a subsequent phase II study failed to demonstrate the single-agent activity of
101 the Aurora kinase inhibitor, alisertib (14,15). Therefore, the development of new therapeutic agents for ULMS remains
102 a challenge.

103 In the present study, we identified that cell cycle-related genes were upregulated and that their kinase activity was
104 predictively activated in ULMS compared with myoma and normal myometrium. With three datasets and our cohort,

35 this is one of the largest research projects assessing the transcriptional landscape of ULMS. Moreover, subsequent
36 analyses showed that PLK1 and CHEK1 inhibition strongly induced cell cycle arrest and exerted superior anti-cancer
37 effects both *in vitro* and *in vivo*.

38

39

10 **Materials and methods**

11 *Patients*

12 Archival fresh-frozen tumor samples stored at the National Cancer Center Biobank (Tokyo, Japan) were used. Since
13 2011, there have been six patients with ULMS who underwent surgery without neoadjuvant therapy. The sarcoma and
14 adjacent myometrium tissues of the six patients were obtained. Moreover, three patients with benign leiomyoma were
15 included as controls. The study protocol was approved by the ethics committee at our institution (approval No.
16 2020-160). We obtained written informed consent from all patients.

17

18 *RNA extraction and transcriptome analysis*

19 Total RNA was extracted from six ULMS and three myoma samples using the miRNeasy Mini Kit (Qiagen, Hilden,
20 Germany), and pair-end sequencing was carried out using a DNBSEQ-G400 (MGI Tech, Shenzhen, China) by Azenta
21 (South Plainfield, NJ). From the sequencing data, expression levels for each gene were quantified by Kallisto (16).
22 Then, the data were summarized using the tximport package (ver. 1.18.0) of R software (ver. 4.0.3) and RStudio
23 (RStudio, Boston, MA), and scaledTPM counts were used for further analysis. Excluding genes with low read
24 coverage (maximum read count: < 100 reads), 3,070 differentially expressed genes (DEGs, $|\log_2FC| > 1$) between the
25 ULMS and myoma samples were used for a heatmap analysis. The heatmap.2 function of the gplots package (ver.
26 3.1.0) was used after the data were converted to base 10 logarithms and z-scores. For volcano plots, the adjusted *P*
27 values for each gene were calculated by the Wald test in DESeq2 (ver. 1.30.0) using data for 23,353 annotated genes.
28 Subsequently, we performed pathway and upstream regulator analysis by Ingenuity Pathway Analysis (IPA, Qiagen)
29 using the significant DEGs identified on the volcano plot.

30

31 *NCBI GEO dataset*

32 The three datasets, GSE36610 (12 ULMS and ten myometrium samples), GSE64763 (25 ULMS, 25 myomas, and 29

33 myometrium samples), and GSE68295 (three ULMS, three myomas, and three myometrium samples), were
34 downloaded from the NCBI GEO database. The three datasets were microarray-based transcriptional profiles, and
35 10,641 common gene symbols were used for analysis (Supplementary Fig. S1A). The expression data were converted
36 to z-scores, and 1,683 DEGs (the difference between the mean z-scores of ULMS and myometrium is greater than 1)
37 were used to generate the heatmap and principal component analysis (PCA). The PCA was visualized using the
38 prcomp and plot3d functions of the rgl package (ver. 0.100.54). For volcano plot, log₂FC and adjusted *P* values for
39 each gene were calculated for each dataset. Then, pathway analysis was performed by IPA using the common DEGs
40 identified on the volcano plots.

41

42 *Cell lines*

43 Three ULMS-derived cell lines, SKN, SK-UT-1, and SK-LMS-1, were used. SKN was purchased from the Japanese
44 Cancer Research Resources Bank (Osaka, Japan), and SK-UT-1 and SK-LMS-1 were purchased from the American
45 Type Culture Collection (Manassas, VA). SKN cells were maintained in Ham's F12 medium (Sigma-Aldrich, St.
46 Louis, MO) containing 10% fetal bovine serum (Thermo Fisher Scientific, Waltham, MA) and antibiotics. SK-UT-1
47 and SK-LMS-1 cells were maintained in MEM (Nacalai Tesque, Kyoto, Japan) containing 10% fetal bovine serum, 1
48 mM sodium pyruvate (Thermo Fisher Scientific), and antibiotics. The cell lines tested negative for mycoplasma
49 contamination and were used between 5 and 40 passages for experiments.

50

51 *Chemicals*

52 All selective kinase inhibitors were purchased from Selleck (Houston, TX), and their putative targets are shown in
53 Supplementally Table S1. Briefly, BI 2536 and volasertib (BI 6727) are PLK1 inhibitors. Prexasertib HCl
54 (LY2606368) and PF-477736 are ATP-competitive CHEK1/2 inhibitors. Dinaciclib (SCH727965) and flavopiridol
55 (Alvocidib) are pan-CDK inhibitors. AT9283 is a JAK2/3 and Aurora A/B inhibitor, and tozasertib (MK-0457) is a
56 pan-Aurora inhibitor. JNJ-7706621 is a pan-CDK and potent Aurora A/B inhibitor, and BAY 1217389 is a TTK
57 inhibitor. Pazopanib is an approved multi-target inhibitor. The drugs were dissolved in DMSO as stock solutions and
58 further diluted in the culture medium for experiments. Moreover, cisplatin was purchased from Nichi-Iko
59 Pharmaceutical (Toyama, Japan).

30

31 *Small interfering RNAs (siRNAs)*

32 SilencerSelect Pre-designed siRNAs for each gene (Thermo Fisher Scientific) were used, and the assay IDs were as
33 follows; s448 (siPLK1 No. 1), s449 (siPLK1 No. 2), s503 (siCHEK1 No. 1), s504 (siCHEK1 No. 2), s22119
34 (siCHEK2 No. 1), and s22121 (siCHEK2 No. 2). Cells were transfected with 3 nM siRNA using Lipofectamine RNAi
35 Max (Thermo Fisher Scientific).

36

37 *Cell viability assay*

38 Cells were seeded into 96-well plates. Immediately after attachment, the cells were treated with the inhibitors and
39 incubated for 72 h. For siRNAs, cells were transfected with the siRNAs and incubated for 24, 48, and 72 h. Cell
40 viability was assessed using the CellTiter-Glo 2.0 Cell Viability Assay (Promega, Madison, WI), and the luminescence
41 measurements were taken 10 min after adding the reagent using a microplate reader (Molecular Devices, San Jose,
42 CA). Viability was calculated with the percentage of untreated cells, and experiments were performed in triplicate and
43 repeated three times. IC50 and drug dose-response curves were calculated in GraphPad Prism 7 (Version 7.0d,
44 GraphPad Software, San Diego, CA). Synergy was determined using CompuSyn software (version 1.0)
45 (<http://www.combosyn.com/index.html>).

46

47 *Cell cycle assay*

48 Cells were seeded in 6-well plates and grown to approximately 80% confluency. Then, cells were treated with
49 selective inhibitors for 24 h. The cells were harvested following trypsinization, washed with 3% FBS/PBS, and fixed
50 in cold 70% ethanol. The cells were then resuspended in 3% FBS/PBS and stained with RaddiDrop Propidium Iodide
51 (Bio-Rad Laboratories, Hercules, CA). Cell analyzer EC800 (Sony, Tokyo, Japan) was used for the analysis. The
52 resulting data were analyzed with FlowJo software (BD Biosciences). Experiments were performed in triplicate and
53 repeated three times.

54

55 *qRT-PCR*

56 Paired ULMS and adjacent normal tissues were used, and total RNA was extracted as described previously. Total RNA
57 was extracted from transfected cells, and cDNA was synthesized using SuperScript III Reverse Transcriptase (Thermo
58 Fisher Scientific). The QuantiTect SYBR Green PCR Kit (Qiagen) or THUNDERBIRD SYBR qPCR Mix (Toyobo,

39 Osaka, Japan) were used. Specific primers were synthesized by Fasmac (Kanagawa, Japan), and the primer sequences
30 are shown in **Supplementary Table S2**. The amplification program was as follows: denaturation at 95°C for 10 min,
31 followed by 40 amplification cycles of 95°C for 15 s and 60°C for 60 s. The amplified product was monitored by
32 measuring SYBR Green I dye fluorescence intensity, and β -actin was used as a reference gene to normalize
33 expression.

34

35 *Western blot analysis*

36 Cells were treated with prexasertib for 16 h, and then, total protein extracts were prepared using the M-PER
37 Mammalian Protein Extraction Reagent (Thermo Fisher Scientific) containing the Halt Protease & Phosphatase
38 Inhibitor Single-Use Cocktail (Thermo Fisher Scientific). After quantification, 10 μ g of total protein was separated on
39 Mini-PROTEAN TGX gels (4%–20%, Bio-Rad Laboratories) and transferred to PVDF membranes. The following
40 primary antibodies were used: Chk1 (2G1D5) Mouse mAb #2360 (Cell Signaling Technology), Phospho-Chk1
41 (Ser296) Antibody #2349 (Cell Signaling Technology), and β -actin (C4) (MAB1501, Merck, Germany). Horseradish
42 peroxidase-conjugated anti-mouse IgG (NA931) and horseradish peroxidase-conjugated anti-rabbit IgG (NA934) were
43 purchased from GE Healthcare (Buckinghamshire, UK). Protein bands were visualized using ImmunoStar LD
44 (Fujifilm Wako Pure Chemical, Osaka, Japan) and ImageQuant LAS-4000 (Fujifilm, Tokyo, Japan).

35

36 *Immunofluorescence*

37 After incubation with a prexasertib-containing medium for 24 h, cells were fixed with 4% paraformaldehyde. The
38 cells were then treated with 0.3% Triton-X/Blocking One solution (Nacalai Tesque). Phospho-Histone H2A.X
39 (Ser139) Antibody #2577 (Cell Signaling Technology, Danvers, MA), Alexa-Fluor 488 Goat anti-Rabbit IgG (H+L)
40 Cross-Absorbed Secondary Antibody (Thermo Fisher Scientific), and Hoechst 33342, trihydrochloride, trihydrate
41 (Thermo Fisher Scientific) were used for detection and staining, and images were captured using a BZ-X700
42 fluorescence microscope (Keyence, Osaka, Japan).

12

14 *Animal studies*

15 All mouse experiments were approved by the National Cancer Center Research Institute, Institute of Laboratory
16 Animal Research (Number: T18-009). Four-week-old female BALB/C nude mice were used for the animal

17 experiments, and 3.0×10^6 SK-UT-1 cells were injected into the right flank of the mice. BI 2536 was dissolved in
18 hydrochloric acid (0.1N) and diluted with 0.9% NaCl. Prexasertib was dissolved in a vehicle (5% DMSO + 40% PEG
19 300 + 5% Tween80 + ddH₂O), and cisplatin was diluted with 0.9% NaCl. The drugs were administered
20 intraperitoneally twice a week. Mice were monitored carefully, and tumor volume was calculated using the modified
21 ellipsoid formula ($\text{Length} \times \text{Width}^2 \times 0.5$). Mice were sacrificed when the tumors reached a volume of 2,000 mm³.

22

23 *Statistical analysis*

24 Statistical analysis was performed with RStudio and R software (ver. 4.0.3). Welch's *t*-test was used to determine the
25 significance of differences between the means of two sets of data. Paired *t*-test was used to determine the significance
26 of differences between the paired LMS and myometrium samples. Dunnett's test was used for multiple comparisons
27 with a control group using the multcomp package (ver. 1.4-17). Kaplan-Meier curves and a log-rank test were used
28 for the analysis of the survival. A *P* value of less than 0.05 was considered statistically significant.

29

30 *Data availability statement*

31 The data generated in this study are publicly available in Gene Expression Omnibus (GEO) at GSE185543.

32

33

34 **Results**

35 *Transcriptome analysis of clinical samples*

36 Transcriptome analysis was performed using six ULMS and three myoma samples. The median age of the patients
37 with ULMS was 59.5 (range, 53–79) years and all patients underwent surgery without neoadjuvant therapy. The
38 heatmap showed that the gene expression profile of ULMS was quite different from that of myoma (Fig. 1A). The
39 expression of 23,353 genes was compared by multivariate analysis. There were 387 significantly upregulated and 125
40 significantly downregulated genes in ULMS based on a cut-off of $|\log_2\text{FC}| > 1$ and an adjusted *P*-value < 0.05 (Fig.
41 1B and Supplementary Table S3 & S4). To assess the putative function of the 512 DEGs, pathway analysis was
42 performed using the IPA software, which revealed that several pathways associated with the cell cycle and DNA
43 damage checkpoint were significantly dysregulated. For example, these included “Kinetochore Metaphase Signaling
44 Pathway ($P = 5.01\text{E-}24$),” “Mitotic Roles of Polo-Like Kinase ($P = 1.58\text{E-}11$),” and “Cell Cycle: G2/M DNA Damage

45 Checkpoint Regulation ($P = 2.51E-7$)” (Fig.1C). In addition, upstream regulator analysis using IPA revealed that the
46 function of CDK1, AURKB, PLK1, CHEK2, CHEK1, CDK2, and PRKDC was significantly activated in ULMS
47 (Fig.1C and Table 1).

48 Then, to validate our results, we used three GEO datasets, which were made up of the expression of 10,641 genes in
49 40 ULMS, 28 myomas, and 42 normal myometrium samples (Supplementary Fig. S1A). The PCA and heatmap
50 analysis showed that the transcriptional profile of ULMS is different from that of myoma and normal myometrium
51 (Fig.1D&1E). Then, comparing ULMS and myometrium samples in each dataset, we identified that 236 and 45 genes
52 were commonly upregulated and downregulated in ULMS, respectively (Fig. 1F and Supplementary Fig. S1A).
53 Moreover, the expression of the seven upstream regulators, which were identified in our cohorts, were confirmed to be
54 upregulated in ULMS (Fig. 1F). Then, the IPA analysis using 281 DEGs validated the activation of “Kinetochores
55 Metaphase Signaling Pathway ($P = 2.58E-18$)” and inhibition of “Cell Cycle: G2/M DNA Damage Checkpoint
56 Regulation ($P = 2.82E-10$)” (Fig. 1G). Therefore, aberrant cell cycle regulation would be a dominant transcriptional
57 feature of ULMS.

58

59 *In vitro screening of selective inhibitors for the activated upstream regulators*

60 We considered the upregulated and activated key regulators as potential therapeutic targets for ULMS. Hence, the
61 anti-cancer effects of selective inhibitors for these genes were evaluated using three cell lines derived from ULMS.
62 First, we evaluated the efficacy of pazopanib, which is an approved drug for malignant soft-tissue tumors. Cells were
63 treated with pazopanib for 72 h, and the IC50 values for SK-UT-1, SK-LMS-1, and SKN cells were 30.7, 62.8, and 5.7
64 μ M, respectively (Supplementary Fig. S2A). Then, we assessed the efficacy of selective inhibitors for the target genes,
65 and most of them were highly effective compared with pazopanib (Fig. 2A&2B and Supplementary Fig. S2B). The
66 inhibitors for PLK1 (BI 2536 and volasertib) exhibited cytotoxicity at a lower nanomolar concentration in SK-UT-1
67 and SK-LMS-1 cells (Fig. 2A). Moreover, CHEK1/2 inhibitor (prexasertib and PF-477736) also showed a higher
68 sensitivity in SK-UT-1 cells, with an IC50 below 10 nM (Fig. 2B). On the other hand, both BI 2536 and prexasertib
69 were less effective in SKN cells compared with SK-UT-1 cells, although their effect was at least ten times greater than
70 that of pazopanib.

71 Then, we evaluated the effect of BI 2536 and prexasertib on the cell cycle. In the 24 hour-treatment, 10 nM BI
72 2536 showed little effect, but 100 nM BI 2536 considerably decreased the cell population in the G1 phase and

73 increased that in the S and G2/M phase (Fig. 2C). Similarly, when treated with 100 nM prexasertib, the cell population
74 in the G1 phase was considerably decreased, whereas that in the S and G2/M phases was considerably increased in all
75 cell lines (Fig. 2D). In particular, SK-UT-1 cells were highly sensitive to prexasertib, and 10 nM prexasertib was
76 enough to induce cell cycle arrest.

77

78 *The effect of PLK1 inhibition*

79 According to the results of integrative transcriptome analysis and drug screening, PLK1 is the most attractive
80 therapeutic target. In our cohort, the expression of *PLK1* was significantly increased in ULMS compared with adjacent
81 normal myometrium ($P < 0.001$, Fig. 3A). Thus, to assess the role of PLK1 in ULMS, we performed gene silencing
82 experiments using siRNAs. Two siRNAs for PLK1 reduced the expression of *PLK1* to about 30–40% and increased
83 the number of the round shape cells (Fig. 3B&3C). The cell cycle analysis showed that siRNAs for PLK1
84 considerably decreased the cell population in the G1 phase and increased that in the S and G2/M phase in all cell lines
85 (Fig. 3D). Therefore, PLK1 knockdown significantly decreased the cell proliferation (in SK-UT-1, SK-LMS-1, and
86 SKN; $P < 0.01$, $P < 0.001$, and $P < 0.01$, respectively, Fig. 3E). In particular, the effect of 3 nM siRNA was almost the
87 same as that of 100 nM BI 2536 and caused complete growth arrest in SK-LMS-1 cells (Fig. 3D&3E).

88

89 *The effect of CHEK1 inhibition*

90 In addition to PLK1 inhibition, CHEK1/2 inhibition is also a promising therapeutic strategy to impair DNA damage
91 response. Both *CHEK1* and *CHEK2* were upregulated in ULMS compared with adjacent normal myometrium ($P <$
92 0.01 and $P < 0.01$). The fold change of CHEK1 is larger than that of CHEK2 (Fig. 4A). The siRNA-mediated
93 downregulation of *CHEK1* and *CHEK2* was confirmed by qRT-PCR, but the effect of siRNAs was different depending
94 on the cell types (Fig. 4B). In SK-UT-1 cells, siRNAs for CHEK1 significantly inhibited cell proliferation ($P < 0.001$),
95 whereas siRNAs for CHEK2 showed no effect on proliferation (Fig. 4C). In SK-LMS-1 and SKN cells, siRNAs for
96 both CHEK1 and CHEK2 slightly but significantly inhibited the proliferation (Fig. 4C). Moreover, prexasertib
97 decreased the expression of pCHEK1(Ser296) in a dose-dependent manner (Fig. 4D). Therefore, CHEK1 was more
98 responsible for the prexasertib-induced growth arrest.

99 To confirm the prexasertib-induced DNA damage, immunocytochemistry for phospho-H2AX was performed. In
100 SK-UT-1 and SKN cells, a 24-hour exposure to 100 nM prexasertib caused structural abnormalities in the nucleus (Fig.

01 4E). Moreover, in all cell lines, the percentage of γ H2AX-positive cells was significantly increased by prexasertib
02 treatment (in SK-UT-1, SK-LMS-1, and SKN; $P < 0.001$, $P < 0.001$, and $P < 0.05$, respectively, Fig. 4E). In addition,
03 increasing DNA damage is expected to enhance the effect of prexasertib, and therefore, we assessed the combination
04 effect of prexasertib and cisplatin. Cells were treated with a combination of various concentrations of prexasertib and
05 cisplatin, and the synergy was determined using CompuSyn software. As a result, cisplatin synergistically enhanced
06 the effect of prexasertib (Fig. 4F).

07

08 *In vivo efficacy of PLK1 and CHEK1 inhibition*

09 Finally, we investigated the *in vivo* efficacy of the inhibitors. SK-UT-1 tumor-bearing mice were treated with either BI
10 2536 (20 mg/kg or 30 mg/kg) or saline for two weeks after implantation. The mice treated with BI 2536 monotherapy
11 exhibited marked tumor regression ($P < 0.001$, Fig. 5A and Supplementary Fig. S3A). The toxicity was well tolerated,
12 and no mice died due to treatment. When the tumor volume of the control mice reached 2,000 mm³, all the mice were
13 sacrificed. The mean tumor weight of the high-dose of BI 2536, low-dose of BI 2536, and control groups were 0.53 g,
14 0.93 g, and 2.24 g, respectively. Hence, BI 2536 monotherapy significantly decreased the tumor weight in a
15 dose-dependent manner (low-dose and high-dose; $P < 0.01$ and $P < 0.01$, respectively, Fig. 5B).

16 Combination therapy is an effective strategy for increasing therapeutic effects and reducing adverse events. We
17 assessed the anti-cancer effect of the combination of prexasertib (3 mg/kg) with cisplatin (3 mg/kg). The prexasertib
18 monotherapy showed no considerable tumor regression effect, whereas cisplatin monotherapy significantly prolonged
19 survival compared with the DMSO treatment ($P < 0.001$, Fig. 5C). When combined with prexasertib and cisplatin, the
20 anti-cancer effect was enhanced, and marked growth inhibition was observed. Thus, compared with DMSO treatment,
21 the combination therapy significantly reduced the tumor volume ($P < 0.05$) and prolonged survival ($P < 0.001$, Fig. 5C
22 and Supplementary Fig. S3B). In the combination therapy group, the tumors of three mice did not reach a volume of
23 2,000 mm³ within 12 weeks. The tumor weights of sacrificed mice were not significantly different between the groups,
24 indicating that the experiment was conducted fairly (Fig. 5C). Moreover, the survival period in the combination group
25 was significantly longer compared with that in the cisplatin monotherapy group ($p < 0.05$, Fig. 5C&5D). Therefore, BI
26 2536 monotherapy and prexasertib plus cisplatin combination therapy caused significant tumor regression in a ULMS
27 mouse model.

28

29

30 **Discussion**

31 In the present study, we identified the key regulators involved in the cell cycle and DNA damage response that
32 activated in ULMS. The regulators, including PLK1 and CHEK1, are potential therapeutic targets, and their selective
33 inhibitors showed outstanding antitumor effects both *in vitro* and *in vivo*.

34 ULMS is one of the most aggressive gynecological malignancies; therefore, the activation of cell cycle-related
35 genes in ULMS is consistent with this phenotype. Previous reports have also shown the alterations in cell cycle-related
36 signaling pathways in ULMS (9,14). Therefore, the activation of these pathways is a dominant feature of ULMS, and
37 they may represent novel therapeutic targets. For example, Aurora kinase A targeted therapy hindered the growth of
38 ULMS in preclinical models, which prompted a clinical trial of alisertib, an Aurora kinase inhibitor (14,15). However,
39 in the phase II trial, which included 23 recurrent/persistent ULMS patients, the median PFS was 1.7 months; thus,
40 alisertib did not demonstrate clinically significant single-agent activity (15). Therefore, it is essential to investigate
41 other cell cycle-related target molecules and drugs.

42 PLK1 is a highly conserved serine/threonine protein kinases and is involved in the regulation of cell division
43 (17,18). PLK1 is overexpressed in various kinds of cancers, and cancer cells often have elevated activity of PLK1
44 (17,18). Hence, PLK1 has been considered a promising therapeutic target, and BI 2536, a prototype PLK1 inhibitor,
45 was developed (19). BI 2536 induced cell cycle arrest and apoptosis and had a greater anti-cancer effect in the mice
46 models (19-22). Therefore, several clinical trials have been conducted. In the phase II trial for advanced non-small cell
47 lung cancer (NSCLC), BI 2536 monotherapy had modest efficacy, and 4.2% of patients had a partial response (23).
48 However, in the other phase II trials, BI 2536 monotherapy showed limited efficacy in various solid tumors (24-26).
49 Then, volasertib was developed, and phase II trials demonstrated insufficient single-agent activity in metastatic
50 urothelial cancer and NSCLC (27,28). Thus, to maximize the therapeutic effect of PLK inhibitors, several studies have
51 investigated combination therapy. The PLK1 and mTOR targeting therapy induced a synergistic effect in squamous
52 cell carcinoma, and histone deacetylase inhibitors also increased the effect of PLK inhibitors synergistically in prostate
53 cancer cells (29,30). Moreover, an alternative approach would be the exploration of predictive biomarkers for PLK1
54 inhibition. In NSCLC, more mesenchymal-like cancer cells were more sensitive to PLK1 inhibitors, and
55 PIM1-overexpressing prostate cancer cells were highly sensitive to BI 2536 (31,32). PIM kinases were reported to
56 have a certain role in sarcoma development in an experimental model (33). Therefore, it is expected that ULMS is

57 highly sensitive to PLK1 inhibition, and a suitable combination of drugs is a rational therapeutic strategy.

58 CHEK1 and CHEK2 are the central regulators of DNA damage response signaling. Briefly, ATR and ATM act as
59 sensors of single-strand and double-strand breaks, respectively, which activate CHEK1 and CHEK2 by
60 phosphorylation. CHEK1 and CHEK2 prevent the removal of phosphates on CDK1 and CDK2 by suppressing
61 CDC25A and CDC25C phosphatases (34). Therefore, activation of CHEK1 and CHEK2 provides the cell time to
62 repair DNA damage. We demonstrated that CHEK1 was more responsible for sarcoma cell proliferation compared
63 with CHEK2. Moreover, previous reports also showed that CHEK1 inhibition causes the inappropriate activation of
64 the CDC25A-CDK2 axis as well as various abnormalities, such as increased double-stranded DNA breaks, the
65 accumulation of aberrant replication fork structures, and the permission to enter the G2/M phase with damaged DNA
66 (35-37). Hence, CHEK1 inhibition may be a novel therapeutic candidate for ULMS. Prexasertib (LY2606368) is an
67 ATP-competitive protein kinase inhibitor with a K_i of 0.9 nmol/L against purified CHEK1. Several studies have
68 shown its excellent antitumor effects in a variety of cancer cells (37-43). Moreover, consistent with our results, a
69 synergistic effect for the combination of prexasertib and cytotoxic drugs or PARP inhibitors has been reported (39-43).
70 In a clinical trial, prexasertib monotherapy demonstrated single-agent activity in heavily pretreated squamous cell
71 carcinoma (44). Moreover, another phase II study also showed the efficacy of prexasertib in *BRCA* wild-type,
72 recurrent high-grade serous ovarian carcinoma (HGSOC), with eight of 24 patients exhibiting partial responses (45).
73 However, the clinical efficacy of prexasertib was modest in advanced *BRCA* wild-type triple-negative breast cancer,
74 despite similar molecular features with HGSOC (46). The posthoc analysis of HGSOC indicated that prexasertib
75 activity might be associated with *CCNE1* amplification and overexpression (45). This result is interesting because
76 *CCNE1* is amplified and overexpressed in ULMS (9). Therefore, the clinical benefit of prexasertib is highly
77 anticipated in ULMS patients.

78 According to clinical trials, the toxicity of BI 2536, volasertib, and prexasertib were well tolerable. In patients
79 who administered BI 2536 or volasertib, neutropenia was the most frequently observed adverse event, and about
80 30%–40% of the patients experienced grade 3 or 4 neutropenia (23-25,27,28). Similarly, hematological adverse events
81 were frequently observed in the patients that were treated with prexasertib, and almost all the patients experienced
82 grade 3 or 4 neutropenia (44-47). Therefore, the hematological toxicity of these drugs should be kept in mind;
83 however, it is important to also note that all clinical trials have concluded the safety profile.

84 There were several limitations to this study. Firstly, we did not assess the regulatory mechanisms responsible for

35 the activation of the cell cycle in ULMS. This would be interesting as it may lead to the identification of new
36 therapeutic targets. Secondly, we primarily investigated the effect of BI 2536 and prexasertib. However, other cell
37 cycle genes are promising targets for cancer therapy (35). In particular, CDKs inhibition is an attractive treatment
38 strategy based on our results. Therefore, we believe that additional research projects will continue to improve the
39 prognosis of patients with ULMS.

40 In conclusion, the overexpression of PLK1 and CHEK1 was one hallmark of ULMS. Both BI 2536 and
41 prexasertib strongly induced cell cycle arrest and inhibited the proliferation of ULMS cells. Therefore, PLK1 or
42 CHEK1 inhibition are promising therapeutic strategies that might improve clinical outcomes for ULMS.

33

34

35 **Acknowledgments**

36 Research reported in this publication was supported by the Program for Promoting the Enhancement of Research
37 Universities as young researcher units for the advancement of new and undeveloped fields at Nagoya University. We
38 thank the National Cancer Center Biobank for providing biological resources. We received technical support from
39 Yuko Fujiwara at the Laboratory of Molecular Carcinogenesis, National Cancer Center Research Institute. Moreover,
40 we thank Enago (www.enago.jp) for the English language review.

41 Financial support: This study was supported by JSPS KAKENHI Grant Numbers 21H02721, 21H03075, and
42 21K16789. Moreover, YOKOYAMA Foundation for Clinical Pharmacology (YRY-2115), Japan Research Foundation
43 for Clinical Pharmacology (2021A18), and Foundation for Promotion of Cancer Research in Japan supported as well.

34

05 **Figure legends**

06 **Fig. 1. The transcriptome analysis of uterine leiomyosarcomas (LMSs) and myomas**

07 (A) The hierarchical clustering and heatmap showing 3,070 differentially expressed genes (DEGs) between the
08 ULMSs and myomas. The DEGs were defined as an absolute log₂ fold change exceeding 1. (B) The volcano plot
09 showing significant DEGs between LMSs and myomas. The adjusted *P* values for each gene were calculated by the
10 Wald test in DESeq2. (C) The top ten significantly dysregulated pathways and the graphical summary based on
11 Ingenuity Pathway Analysis (IPA) for the significant DEGs. The orange and blue nodes represent the activated and
12 inhibited genes or pathways, respectively. The orange arrows and blue inhibitory arrows indicate activation and
13 suppression, respectively. (D) The principal component analysis (E) The hierarchical clustering and heatmap for
14 GSE36610, GSE64763, and GSE68295 dataset. Each data was converted to z-scores and merged. Comparing the
15 mean expression of ULMS and myometrium, 1,683 DEGs were used for analyses. (F) The Venn diagram showing the
16 significantly upregulated and downregulated genes between ULMS and myometrium in each dataset. The name of
17 seven predictively activated upstream regulators in ULMS is shown. (G) The top ten significantly dysregulated
18 pathways for the three datasets. The IPA analysis was performed using the 282 significant DEGs in common.

19

20 **Fig. 2. The inhibitory effects of PLK1 or CHEK1/2 inhibitors**

21 (A) The effect of PLK1 inhibitors; BI 2536 and volasertib. (B) The effect of CHEK1/2 inhibitors; prexasertib and
22 PF-477736. Cells were treated with each inhibitor for 72 h. Red, green, and blue represent SK-UT-1, SK-LMS-1, and
23 SKN, respectively. Experiments were performed in triplicate and repeated three times, and IC₅₀ and drug
24 dose-response curves were calculated in GraphPad Prism 7. (C) Cell-cycle distribution of BI 2536-treated cells. (D)
25 Cell-cycle distribution of prexasertib-treated cells. Cells were treated with each concentration of inhibitor for 24 h.
26 Cell-cycle distribution was calculated by FlowJo, and the percentage of cells was compared using Dunnett's test. Error
27 bars represent standard errors of the mean.

28

29 **Fig. 3. The effects of PLK1 silencing**

30 (A) The relative expression of *PLK1* in paired ULMS and myometrium. The relative expression was compared using
31 paired *t*-test. (B) Validation of *PLK1* suppression following transfection with 3 nM of siRNA for PLK1 (siPLK1). (C)
32 The representative images of siPLK1 transfected cells. Scale bars show 100 μm. (D) Cell-cycle distribution of siPLK1

33 transfected cells. Cell-cycle distribution was calculated by FlowJo, and the percentage of cells was compared using
34 Dunnett's test. **(E)** The proliferation of siPLK1 transfected cells. Cell viability was measured at 24, 48, and 72 h, and
35 the luminescence was compared using Dunnett's test. Error bars represent standard errors of the mean, * $P < 0.05$, ** P
36 < 0.01 , and *** $P < 0.001$.

37

38 **Fig. 4. The effects of CHEK1 silencing and prexasertib**

39 **(A)** The relative expression of *CHEK1* and *CHEK2* in paired ULMS and myometrium. The relative expression was
40 compared using paired *t*-test. **(B)** Validation of *CHEK1* or *CHEK2* suppression following transfection with 3 nM of
41 siRNA for CHEK1 (siCHEK1) or CHEK2 (siCHEK2). **(C)** The proliferation of siCHEK1 transfected cells. Cell
42 viability was measured at 24, 48, and 72 h, and luminescence was compared using Dunnett's test. **(D)** The expression
43 of CHEK1 and pCHEK1(Ser296) protein in prexasertib-treated cells. Cells were treated with each concentration of
44 prexasertib for 16 h. **(E)** Immunofluorescent of γ H2AX in prexasertib-treated cells. Cells were treated with 0 or 100
45 nM prexasertib for 24 h, and the percentage of γ H2AX cells was determined. Green and blue colors indicate γ H2AX
46 and Hoechst, respectively, and scale bars represent 10 μ m. The percentage of γ H2AX-positive cells was compared
47 using Welch's *t*-test. **(F)** The combination effect of prexasertib and cisplatin. Cells were treated with each drug
48 concentration for 72 h, and the percentage of growth inhibition is shown relative to untreated controls. Drug synergy
49 was analyzed using CompuSyn software. Error bars represent standard errors of the mean, * $P < 0.05$, ** $P < 0.01$, and
50 *** $P < 0.001$.

51

52 **Fig. 5. In vivo efficacy of BI 2536 or prexasertib**

53 **(A)** Estimated tumor volume of SK-UT-1 tumor-bearing mice treated with either BI 2536 monotherapy or saline ($n = 6$
54 per group). High-dose (30 mg/kg), low-dose (20 mg/kg) of BI 2536, or saline was intraperitoneally administered twice
55 a week for four weeks. **(B)** The representative images of tumors and the mean tumor volume of SK-UT-1
56 tumor-bearing mice treated with either BI 2536 or saline. The mice were sacrificed when the tumors of the control
57 mice reached a volume of 2,000 mm³. **(C)** Estimated tumor volume and Kaplan-Meier plot of SK-UT-1 tumor-bearing
58 mice treated with prexasertib and cisplatin in combination ($n = 7$ per group). Prexasertib (3 mg/kg), cisplatin (3
59 mg/kg), the combination of prexasertib (3 mg/kg) plus cisplatin (3 mg/kg), or vehicle (DMSO) was intraperitoneally
60 administered twice a week for four weeks. The mice were sacrificed when the tumors reached a volume of 2,000 mm³.

31 The tumor volume and weight were compared using Welch's *t*-test, and survival was compared by a log-rank test. **(D)**
32 The representative images of tumors and the mean tumor volume of SK-UT-1 tumor-bearing mice treated with The
33 prexasertib and cisplatin combination therapy. The tumor weight was compared using Dunnett's test. The scale bars
34 represent 1 cm. The error bars represent the standard errors of the mean. **P* < 0.05, ***P* < 0.01, and ****P* < 0.001
35 (compared with control mice). †*P* < 0.05 and ††*P* < 0.01 (compared with cisplatin-treated mice), N.S., not significant.

36
37

38 **Supplementary Figure S1. The analysis of three GEO datasets**

39 **(A)** The Venn diagram showing common gene symbols in GSE36610, GSE64763, and GSE68295. **(B)** The volcano
40 plot showing significant DEGs between LMSs and myometrium in each dataset. The adjusted *P* values for each gene
41 were calculated by the Wald test in DESeq2.

42

43 **Supplementary Figure S2. The inhibitory effects of selective inhibitors**

44 **(A)** The effect of an approved drug, pazopanib. **(B)** The effect of dinaciclib, flavopiridol, AT9283, tozasertib,
45 JNJ-7706621, and BAY 1217389. Dinaciclib and flavopiridol are pan-CDK inhibitors. AT9283 is a JAK2/3 and
46 Aurora A/B inhibitor, and tozasertib is a pan-Aurora inhibitor. JNJ-7706621 is a pan-CDK and potent Aurora A/B
47 inhibitor, and BAY 1217389 is a TTK inhibitor. The cells were treated with each inhibitor for 72 h. Red, green, and
48 blue represent SK-UT-1, SK-LMS-1, and SKN, respectively. Experiments were performed in triplicate and repeated
49 three times, and IC50 and drug dose-response curves were calculated in GraphPad Prism 7.

50

51 **Supplementary Figure S3. Tumor growth in SK-UT-1 tumor-bearing mice**

52 **(A)** The estimated tumor volume of SK-UT-1 tumor-bearing mice treated with either BI 2536 monotherapy or saline.
53 High-dose (30 mg/kg), low-dose (20 mg/kg) of BI 2536, or saline were intraperitoneally administered twice a week
54 for four weeks. **(B)** The estimated tumor volume of SK-UT-1 tumor-bearing mice treated with prexasertib and
55 cisplatin combination therapy. Prexasertib (3 mg/kg), cisplatin (3 mg/kg), the combination of prexasertib (3 mg/kg)
56 plus cisplatin (3 mg/kg), or vehicle (DMSO) was intraperitoneally administered twice a week for four weeks.

57

38 References

- 39 1. Roberts ME, Aynardi JT, Chu CS. Uterine leiomyosarcoma: A review of the literature and update on
40 management options. *Gynecol Oncol* 2018; **151**(3):562-72.
- 91 2. George S, Serrano C, Hensley ML, Ray-Coquard I. Soft tissue and uterine leiomyosarcoma. *J Clin Oncol*
92 2018; **36**(2):144-50.
- 93 3. Skorstad M, Kent A, Lieng M. Uterine leiomyosarcoma - incidence, treatment, and the impact of
94 morcellation. A nationwide cohort study. *Acta Obstet Gynecol Scand* 2016; **95**(9):984-90.
- 95 4. Seagle BL, Sobocki-Rausch J, Strohl AE, Shilpi A, Grace A, Shahabi S. Prognosis and treatment of uterine
96 leiomyosarcoma: A National Cancer Database study. *Gynecol Oncol* 2017; **145**(1):61-70.
- 97 5. Abeler VM, Røyne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in
98 Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419
99 patients. *Histopathology* 2009; **54**(3):355-64.
- 30 6. Hensley ML, Patel SR, von Mehren M, Ganjoo K, Jones RL, Staddon A, *et al* Efficacy and safety of
31 trabectedin or dacarbazine in patients with advanced uterine leiomyosarcoma after failure of
32 anthracycline-based chemotherapy: Subgroup analysis of a phase 3, randomized clinical trial. *Gynecol*
33 *Oncol* 2017; **146**(3):531-7.
- 34 7. Blay JY, Schöffski P, Bauer S, Krarup-Hansen A, Benson C, D'Adamo DR, *et al* Eribulin versus
35 dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised
36 study. *Br J Cancer* 2019; **120**(11):1026-32.
- 37 8. Benson C, Ray-Coquard I, Sleijfer S, Litière S, Blay JY, Le Cesne A, *et al* Outcome of uterine sarcoma
38 patients treated with pazopanib: A retrospective analysis based on two European Organisation for
39 Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials
40 62043 and 62072. *Gynecol Oncol* 2016; **142**(1):89-94.
- 41 9. Cuppens T, Moisse M, Depreeuw J, Annibaldi D, Colas E, Gil-Moreno A, *et al* Integrated genome analysis
42 of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. *Int J Cancer*
43 2018; **142**(6):1230-43.
- 44 10. Hensley ML, Chavan SS, Solit DB, Murali R, Soslow R, Chiang S, *et al* Genomic landscape of uterine
45 sarcomas defined through prospective clinical sequencing. *Clin Cancer Res* 2020; **26**(14):3881-8.
- 46 11. Astolfi A, Nannini M, Indio V, Schipani A, Rizzo A, Perrone AM, *et al* Genomic database analysis of
47 uterine leiomyosarcoma mutational profile. *Cancers (Basel)* 2020; **12**(8).
- 48 12. Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, *et al* Integrated mutational landscape
49 analysis of uterine leiomyosarcomas. *Proc Natl Acad Sci USA* 2021; **118**(15).
- 50 13. Mas A, Alonso R, Garrido-Gómez T, Escorcía P, Montero B, Jiménez-Almazán J, *et al* The differential
51 diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing. *Am J Obstet*
52 *Gynecol* 2019; **221**(4):320.e1-e23.
- 53 14. Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, *et al* A
54 small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine
55 leiomyosarcoma. *Clin Cancer Res* 2012; **18**(12):3352-65.
- 56 15. Hyman DM, Sill MW, Lankes HA, Piekarz R, Shahin MS, Ridgway MR, *et al* A phase 2 study of alisertib

- 27 (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology
28 Group study 0231D. *Gynecol Oncol* 2017; **144**(1):96-100.
- 29 16. Bray NL, Pimentel H, Melsted P, Pachter L. Near-optimal probabilistic RNA-seq quantification. *Nat*
30 *Biotechnol* 2016; **34**(5):525-7.
- 31 17. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
32 *Oncologist* 2009; **14**(6):559-70.
- 33 18. Archambault V, Lépine G, Kachaner D. Understanding the Polo Kinase machine. *Oncogene*
34 2015; **34**(37):4799-807.
- 35 19. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, *et al* BI 2536, a potent and
36 selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. *Curr Biol* 2007; **17**(4):316-22.
- 37 20. Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, *et al* Combined gene expression profiling
38 and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.
39 *Cancer Res* 2011; **71**(15):5225-34.
- 40 21. Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, *et al* Small molecule kinase inhibitor
41 screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. *Cancer Res*
42 2011; **71**(4):1385-95.
- 43 22. Maire V, Némati F, Richardson M, Vincent-Salomon A, Tesson B, Rigai G, *et al* Polo-like kinase 1: a
44 potential therapeutic option in combination with conventional chemotherapy for the management of
45 patients with triple-negative breast cancer. *Cancer Res* 2013; **73**(2):813-23.
- 46 23. Sebastian M, Reck M, Waller CF, Kortsik C, Frickhofen N, Schuler M, *et al* The efficacy and safety of BI
47 2536, a novel Plk-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed
48 after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. *J Thorac*
49 *Oncol* 2010; **5**(7):1060-7.
- 50 24. Mross K, Dittrich C, Aulitzky WE, Strumberg D, Schutte J, Schmid RM, *et al* A randomised phase II trial
51 of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine
52 adenocarcinoma of the pancreas - a study within the Central European Society Anticancer Drug Research
53 (CESAR) collaborative network. *Br J Cancer* 2012; **107**(2):280-6.
- 54 25. Awad MM, Chu QS, Gandhi L, Stephenson JJ, Govindan R, Bradford DS, *et al* An open-label, phase II
55 study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer
56 (SCLC). *Lung Cancer* 2017; **104**:126-30.
- 57 26. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, *et al* Multicentric parallel phase II trial
58 of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer,
59 ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for
60 Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). *Eur J Cancer*
61 2010; **46**(12):2206-15.
- 62 27. Stadler WM, Vaughn DJ, Sonpavde G, Vogelzang NJ, Tagawa ST, Petrylak DP, *et al* An open-label,
63 single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally
64 advanced or metastatic urothelial cancer. *Cancer* 2014; **120**(7):976-82.
- 65 28. Ellis PM, Leighl NB, Hirsh V, Reaume MN, Blais N, Wierzbicki R, *et al* A Randomized, Open-Label Phase

- 36 II Trial of Volasertib as Monotherapy and in Combination With Standard-Dose Pemetrexed Compared
37 With Pemetrexed Monotherapy in Second-Line Treatment for Non-Small-Cell Lung Cancer. *Clin Lung*
38 *Cancer* 2015; **16**(6):457-65.
- 39 29. Wissing MD, Mendonca J, Kortenhorst MS, Kaelber NS, Gonzalez M, Kim E, *et al*. Targeting prostate
40 cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone
41 deacetylase inhibitors. *Faseb j* 2013; **27**(10):4279-93.
- 42 30. Liu TT, Yang KX, Yu J, Cao YY, Ren JS, Hao JJ, *et al*. Co-targeting PLK1 and mTOR induces synergistic
43 inhibitory effects against esophageal squamous cell carcinoma. *J Mol Med (Berl)* 2018; **96**(8):807-17.
- 44 31. Ferrarotto R, Goonatilake R, Yoo SY, Tong P, Giri U, Peng S, *et al*. Epithelial-Mesenchymal Transition
45 Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer. *Clin Cancer*
46 *Res* 2016; **22**(7):1674-86.
- 47 32. van der Meer R, Song HY, Park SH, Abdulkadir SA, Roh M. RNAi screen identifies a synthetic lethal
48 interaction between PIM1 overexpression and PLK1 inhibition. *Clin Cancer Res* 2014; **20**(12):3211-21.
- 49 33. Narlik-Grassow M, Blanco-Aparicio C, Cecilia Y, Peregrina S, Garcia-Serelde B, Muñoz-Galvan S, *et al*.
50 The essential role of PIM kinases in sarcoma growth and bone invasion. *Carcinogenesis*
51 2012; **33**(8):1479-86.
- 52 34. Lin AB, McNeely SC, Beckmann RP. Achieving precision death with cell-cycle inhibitors that target DNA
53 replication and repair. *Clin Cancer Res* 2017; **23**(13):3232-40.
- 54 35. Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. *Nat Rev Cancer*
55 2017; **17**(2):93-115.
- 56 36. Syljuåsen RG, Sørensen CS, Hansen LT, Fugger K, Lundin C, Johansson F, *et al*. Inhibition of human
57 Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage.
58 *Mol Cell Biol* 2005; **25**(9):3553-62.
- 59 37. King C, Diaz HB, McNeely S, Barnard D, Dempsey J, Blosser W, *et al*. LY2606368 causes replication
60 catastrophe and antitumor effects through CHK1-dependent mechanisms. *Mol Cancer Ther*
61 2015; **14**(9):2004-13.
- 62 38. Nair J, Huang TT, Murai J, Haynes B, Steeg PS, Pommier Y, *et al*. Resistance to the CHK1 inhibitor
63 prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer. *Oncogene*
64 2020; **39**(33):5520-35.
- 65 39. Parmar K, Kochupurakkal BS, Lazaro JB, Wang ZC, Palakurthi S, Kirschmeier PT, *et al*. The CHK1
66 inhibitor prexasertib exhibits monotherapy activity in high-grade serous ovarian cancer models and
67 sensitizes to PARP inhibition. *Clin Cancer Res* 2019; **25**(20):6127-40.
- 68 40. Mani C, Jonnalagadda S, Lingareddy J, Awasthi S, Gmeiner WH, Palle K. Prexasertib treatment induces
69 homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
70 *Breast Cancer Res* 2019; **21**(1):104.
- 71 41. Lowery CD, Dowless M, Renschler M, Blosser W, VanWye AB, Stephens JR, *et al*. Broad spectrum activity
72 of the checkpoint kinase 1 inhibitor prexasertib as a single agent or chemopotentiator across a range of
73 preclinical pediatric tumor models. *Clin Cancer Res* 2019; **25**(7):2278-89.
- 74 42. Sen T, Tong P, Stewart CA, Cristea S, Valliani A, Shames DS, *et al*. CHK1 inhibition in small-cell lung

- 35 cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with
36 cisplatin or olaparib. *Cancer Res* 2017; **77**(14):3870-84.
- 37 43. Heidler CL, Roth EK, Thiemann M, Blattmann C, Perez RL, Huber PE, *et al* Prexasertib (LY2606368)
38 reduces clonogenic survival by inducing apoptosis in primary patient-derived osteosarcoma cells and
39 synergizes with cisplatin and talazoparib. *Int J Cancer* 2020; **147**(4):1059-70.
- 40 44. Hong DS, Moore K, Patel M, Grant SC, Burris HA, 3rd, William WN, Jr., *et al* Evaluation of prexasertib,
41 a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma. *Clin Cancer*
42 *Res* 2018; **24**(14):3263-72.
- 43 45. Lee JM, Nair J, Zimmer A, Lipkowitz S, Annunziata CM, Merino MJ, *et al* Prexasertib, a cell cycle
44 checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a
45 first-in-class proof-of-concept phase 2 study. *Lancet Oncol* 2018; **19**(2):207-15.
- 46 46. Gatti-Mays ME, Karzai FH, Soltani SN, Zimmer A, Green JE, Lee MJ, *et al* A phase II single arm pilot
47 study of the CHK1 inhibitor prexasertib (LY2606368) in BRCA wild-type, advanced triple-negative breast
48 cancer. *Oncologist* 2020.
- 49 47. Iwasa S, Yamamoto N, Shitara K, Tamura K, Matsubara N, Tajimi M, *et al* Dose-finding study of the
50 checkpoint kinase 1 inhibitor, prexasertib, in Japanese patients with advanced solid tumors. *Cancer Sci*
51 2018; **109**(10):3216-23.
52

Figure 1





Figure 2

Figure 3




Figure 4




Figure 5.









Table 1. The list of upstream regulators and their target molecules

Upstream Regulator (kinase)	Predicted Activation State	Target Molecules in Dataset	P value of overlap
CDK1	Activated	AURKB, BIRC5, BUB1, BUB1B, CDC20, CDC25A, CDC25C, CDC6, CDT1, FEN1, FOXM1, GAS2L3, H2AX, MCM4, PBK, PLK1, PTTG1, SGO1, STMN1, TTK	7.63E-10
AURKB	Activated	AURKB, BIRC5, CDCA8, CENPA, DTL, KIF2C, SGO2, SKA1, SKA3, TOP2A	6.24E-09
PLK1	Activated	BIRC5, BUB1, BUB1B, CCNB1, CDC20, CDC25C, CEP55, FBXO5, GTSE1, H2AX, HAUS8, KIF2C, KIF1C, PTEN	2.48E-08
CHEK2	Activated	BIRC5, CDC25A, CDC25C, CDK1, FOXM1, TTK	4.84E-05
CHEK1	Activated	CDC25A, CDC25C, CHEK1, CLSPN, E2F7, E2F8, H2AX	1.46E-04
TTK		BUB1, BUB1B, KNL1, RMI2	1.53E-04
CDK2	Activated	CCNA2, CDC25A, CDC6, CDK1, CDT1, CHEK1, KIF11, MCM4, MYBL2, PTTG1	5.66E-04
CDKN1A		CDC6, CDK1, CDT1, CHEK1, H2AX	8.10E-04
WEE1		CDK1, H2AX, STMN1	0.002
PRKDC	Activated	CBX5, CHEK1, H2AX, PLK1, TPX2	0.002
PLK3		CDC25C, H2AX, PTEN	0.003
MAPK9		CBX7, CCND3, CDC25A, CDC25C, CHEK1, H2AX	0.004
CCNB1		BIRC5, BUB1, CDC25A, PBK	0.006
RPS6KA3		CHEK1, H2AX, NEK2, SHANK3, STMN1	0.009
BUB1B		BUB1B, CDC20	0.013
RPS6KA2		CHEK1, FBXO5, NEK2	0.016